Literature DB >> 11585784

Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection.

S D Lawn1, S T Butera, T M Folks.   

Abstract

The life cycle of human immunodeficiency virus type 1 (HIV-1) is intricately related to the activation state of the host cells supporting viral replication. Although cellular activation is essential to mount an effective host immune response to invading pathogens, paradoxically the marked systemic immune activation that accompanies HIV-1 infection in vivo may play an important role in sustaining phenomenal rates of HIV-1 replication in infected persons. Moreover, by inducing CD4+ cell loss by apoptosis, immune activation may further be central to the increased rate of CD4+ cell turnover and eventual development of CD4+ lymphocytopenia. In addition to HIV-1-induced immune activation, exogenous immune stimuli such as opportunistic infections may further impact the rate of HIV-1 replication systemically or at localized anatomical sites. Such stimuli may also lead to genotypic and phenotypic changes in the virus pool. Together, these various immunological effects on the biology of HIV-1 may potentially enhance disease progression in HIV-infected persons and may ultimately outweigh the beneficial aspects of antiviral immune responses. This may be particularly important for those living in developing countries, where there is little or no access to antiretroviral drugs and where frequent exposure to pathogenic organisms sustains a chronically heightened state of immune activation. Moreover, immune activation associated with sexually transmitted diseases, chorioamnionitis, and mastitis may have important local effects on HIV-1 replication that may increase the risk of sexual or mother-to-child transmission of HIV-1. The aim of this paper is to provide a broad review of the interrelationship between immune activation and the immunopathogenesis, transmission, progression, and treatment of HIV-1 infection in vivo.

Entities:  

Mesh:

Year:  2001        PMID: 11585784      PMCID: PMC89002          DOI: 10.1128/CMR.14.4.753-777.2001

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  375 in total

1.  HIV type 1 grown on interferon gamma-treated U937 cells shows selective increase in virion-associated intercellular adhesion molecule 1 and HLA-DR and enhanced infectivity for CD4-negative cells.

Authors:  C Castilletti; M R Capobianchi; S Fais; I Abbate; B Ficociello; F Ameglio; P Cordiali Fei; S M Santini; F Dianzani
Journal:  AIDS Res Hum Retroviruses       Date:  1995-05       Impact factor: 2.205

2.  HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time.

Authors:  A S Perelson; A U Neumann; M Markowitz; J M Leonard; D D Ho
Journal:  Science       Date:  1996-03-15       Impact factor: 47.728

3.  Interleukin 1 induces HIV-1 expression in chronically infected U1 cells: blockade by interleukin 1 receptor antagonist and tumor necrosis factor binding protein type 1.

Authors:  E V Granowitz; B M Saget; M Z Wang; C A Dinarello; P R Skolnik
Journal:  Mol Med       Date:  1995-09       Impact factor: 6.354

4.  Generalized immune activation in pulmonary tuberculosis: co-activation with HIV infection.

Authors:  G Vanham; K Edmonds; L Qing; D Hom; Z Toossi; B Jones; C L Daley; B Huebner; L Kestens; P Gigase; J J Ellner
Journal:  Clin Exp Immunol       Date:  1996-01       Impact factor: 4.330

5.  Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission. Effect of maternal zidovudine treatment on viral load.

Authors:  R E Dickover; E M Garratty; S A Herman; M S Sim; S Plaeger; P J Boyer; M Keller; A Deveikis; E R Stiehm; Y J Bryson
Journal:  JAMA       Date:  1996-02-28       Impact factor: 56.272

6.  A community-based study of human immunodeficiency virus type 2 provirus load in rural village in West Africa.

Authors:  K Ariyoshi; N Berry; A Wilkins; D Ricard; P Aaby; A Nauclér; P T Ngom; O Jobe; S Jaffar; F Dias; R S Tedder; H Whittle
Journal:  J Infect Dis       Date:  1996-01       Impact factor: 5.226

7.  Impairment of tetanus toxoid-specific Th1-like immune responses in humans infected with Schistosoma mansoni.

Authors:  E A Sabin; M I Araujo; E M Carvalho; E J Pearce
Journal:  J Infect Dis       Date:  1996-01       Impact factor: 5.226

8.  The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection.

Authors:  J D Klausner; S Makonkawkeyoon; P Akarasewi; K Nakata; W Kasinrerk; L Corral; R L Dewar; H C Lane; V H Freedman; G Kaplan
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1996-03-01

9.  Maternal plasma human immunodeficiency virus type 1 RNA level: a determinant and projected threshold for mother-to-child transmission.

Authors:  G Fang; H Burger; R Grimson; P Tropper; S Nachman; D Mayers; O Weislow; R Moore; C Reyelt; N Hutcheon; D Baker; B Weiser
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-19       Impact factor: 11.205

10.  Activation of virus replication after vaccination of HIV-1-infected individuals.

Authors:  S I Staprans; B L Hamilton; S E Follansbee; T Elbeik; P Barbosa; R M Grant; M B Feinberg
Journal:  J Exp Med       Date:  1995-12-01       Impact factor: 14.307

View more
  102 in total

1.  Impact of tuberculosis on maternal and child health.

Authors:  Ben J Marais
Journal:  J Infect Dis       Date:  2011-02-01       Impact factor: 5.226

2.  Persistent HIV Type 1 Seronegative Status Is Associated With Lower CD8+ T-Cell Activation.

Authors:  Peter J Kuebler; Megha L Mehrotra; Brian I Shaw; Kaitlyn S Leadabrand; Jeffrey M Milush; Vanessa A York; Patricia Defechereux; Robert M Grant; Esper G Kallás; Douglas F Nixon
Journal:  J Infect Dis       Date:  2015-08-26       Impact factor: 5.226

3.  Cerebrospinal fluid HIV-1 viral load during treatment of cryptococcal Meningitis.

Authors:  Annemarie E Brouwer; Praprit Teparrukkul; Adul Rajanuwong; Wirongrong Chierakul; Weera Mahavanakul; Wasun Chantratita; Nicholas J White; Thomas S Harrison
Journal:  J Acquir Immune Defic Syndr       Date:  2010-04       Impact factor: 3.731

Review 4.  Antiretroviral treatment interruptions and risk of non-opportunistic diseases.

Authors:  Kenneth A Lichtenstein
Journal:  Curr HIV/AIDS Rep       Date:  2009-05       Impact factor: 5.071

5.  Association between latent proviral characteristics and immune activation in antiretrovirus-treated human immunodeficiency virus type 1-infected adults.

Authors:  Emily C Liang; Lindsay Sceats; Nicholas L Bayless; Dara M Strauss-Albee; Jessica Kubo; Philip M Grant; David Furman; Manisha Desai; David A Katzenstein; Mark M Davis; Andrew R Zolopa; Catherine A Blish
Journal:  J Virol       Date:  2014-05-21       Impact factor: 5.103

6.  Comprehensive analysis of frequency and phenotype of T regulatory cells in HIV infection: CD39 expression of FoxP3+ T regulatory cells correlates with progressive disease.

Authors:  Julian Schulze Zur Wiesch; Adriana Thomssen; Philip Hartjen; Ilona Tóth; Clara Lehmann; Dirk Meyer-Olson; Kristina Colberg; Sebastian Frerk; Dalia Babikir; Stefan Schmiedel; Olaf Degen; Stefan Mauss; Jürgen Rockstroh; Schlomo Staszewski; Pavel Khaykin; Alexander Strasak; Ansgar W Lohse; Gerd Fätkenheuer; Joachim Hauber; Jan van Lunzen
Journal:  J Virol       Date:  2010-11-03       Impact factor: 5.103

Review 7.  Chronic immune activation associated with chronic helminthic and human immunodeficiency virus infections: role of hyporesponsiveness and anergy.

Authors:  Gadi Borkow; Zvi Bentwich
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

Review 8.  Clinically relevant drug-drug interactions between antiretrovirals and antifungals.

Authors:  Ramya Krishna Vadlapatla; Mitesh Patel; Durga K Paturi; Dhananjay Pal; Ashim K Mitra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2014-02-12       Impact factor: 4.481

9.  Maternal Humoral Immune Correlates of Peripartum Transmission of Clade C HIV-1 in the Setting of Peripartum Antiretrovirals.

Authors:  Charmaine P Mutucumarana; Joshua Eudailey; Erin P McGuire; Nathan Vandergrift; Gerald Tegha; Charles Chasela; Sascha Ellington; Charles van der Horst; Athena P Kourtis; Sallie R Permar; Genevieve G Fouda
Journal:  Clin Vaccine Immunol       Date:  2017-08-04

10.  Impact of mucosal inflammation on cervical human immunodeficiency virus (HIV-1)-specific CD8 T-cell responses in the female genital tract during chronic HIV infection.

Authors:  Pamela P Gumbi; Nonhlanhla N Nkwanyana; Alfred Bere; Wendy A Burgers; Clive M Gray; Anna-Lise Williamson; Margaret Hoffman; David Coetzee; Lynette Denny; Jo-Ann S Passmore
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.